Correction to: Cancer Cell Int (2020) 20:456 10.1186/s12935-020-01546-8
Following publication of the original article [1], we were notified the Department of Virology, Pasteur Institute of Iran should have been mentioned as the only affiliation for the first and last author. The revised affiliation is reflected in this correction article.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Reference
- 1.Miri SM, et al. CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy. Caner Cell Int. 2020;20:456. doi: 10.1186/s12935-020-01546-8. [DOI] [PMC free article] [PubMed] [Google Scholar]